Pacific Biosciences stock crossed below its 20-day moving average on November 9, 2026, pulling back to 1.98 EUR, boerse.de reported.
The drop follows a longer upward push that started on September 25, 2026. During that multi-week run, the stock gained 50.86 percent. Despite the recent dip below the 20-day line, the share price remains 45.96 percent above its 200-day moving average, according to boerse.de.
Technical indicators currently place the stock in a short-term downward trend while medium- and long-term trends stay positive. A small gain of 1.79 percent would push the price back above the 20-day moving average sitting at 2.02 EUR, restoring upward momentum across all time horizons. If the stock avoids further trendline breaks, the next target sits at the 24-month high of 2.66 EUR reached on October 29, 2026, offering potential upside of 34.34 percent.
Longer performance windows show multi-year changes. The six-month and 12-month metrics reflect a high of 2.66 EUR and a low of 0.83 EUR and 0.80 EUR respectively, marking a 49.62 percent decline from that recent peak. Over three, four, and five-year stretches, the stock traded as high as 13.00 EUR in June 2023 and 30.11 EUR in June 2021 before touching lows of 0.80 EUR in May 2025.
Financial metrics from the company’s preceding fiscal year provide foundational context for its operations. Pacific Biosciences generated 160.01 million USD in revenue, marking a 3.89 percent increase compared to the previous year. Operating losses reached 551.7 million USD, a worsening of 107.84 percent, while the annual net loss was 546.38 million USD, a worsening of 76.34 percent.
The company held a total balance sheet sum of 784.08 million USD at the close of the financial year, with reported equity standing at 5.35 million USD and an equity ratio of 0.68 percent. Total liabilities reached 702.42 million USD, producing a debt-to-assets ratio of 89.59 percent. Headcount decreased by 15.65 percent over the year to 485 employees, resulting in revenue per employee of 0.33 million USD. The firm issued no dividend for the completed fiscal year.
